AGP Executive Report
Last update: 6 hours agoDiagnostics & Access: NICE is backing interim NHS funding for two non-invasive endometriosis tests—EndoSure (gut electrical signals) and Endotest (AI-read saliva microRNA)—aimed at cutting the UK’s ~9-year average diagnosis delay. Patient Safety in Digital Care: A Yale “secret shopper” study in JAMA found many telehealth GLP-1 sites prescribed with limited clinician interaction, raising oversight concerns. Drug Pricing & Coverage: Copay accumulator programs are being criticized after some insurers keep manufacturer copay help meant to lower patient drug costs. Policy & Cost Pressure: The AHA urged the U.S. trade office to exempt medications and medical devices from proposed import duties. Oncology Advances: FDA approved durvalumab plus BCG for high-risk non-muscle-invasive bladder cancer, adding a new option beyond BCG. Prosthetics Research: A new neural-machine interface study suggests the brain processes prosthetic “movement” signals as coordinated grasp patterns, potentially improving sensation and control. Behavioral Health Funding: HHS/SAMHSA announced $281M+ in grants for addiction, overdose, and mental illness programs.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[The Changing Reality of Pharmaceutical Commercialization in a Cold Chain-Driven Market]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/26469006-924977656-01537484a6e83976c89592331f96e5b98edb7bd2-1280x720-100x56.jpeg)
